LDL & HDL Cholesterol
For informational purposes only — not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen. Full disclaimer →
- LDL-C measures cholesterol content, not particle number. Two people with identical LDL-C can have very different atherogenic risk depending on whether their LDL particles are large and buoyant (lower risk) or small and dense (higher risk). ApoB directly counts every atherogenic particle.
- The longevity-optimal LDL-C target is below 70 mg/dL — considerably lower than the standard 'optimal' of below 100 mg/dL. This reflects the level seen in populations with essentially zero atherosclerosis progression.
- HDL-C above 60 mg/dL provides progressively diminishing benefit. Very high HDL-C (above 90–100 mg/dL) may indicate dysfunctional HDL and is associated with elevated cardiovascular risk in several large cohort studies.
- The LDL-C/HDL-C ratio and triglyceride/HDL-C ratio are more informative than either value alone. These ratios capture the metabolic context that single-marker readings miss.
- Always pair with ApoB for the complete picture. ApoB is the superior cardiovascular risk marker and directly measures what LDL-C approximates. When LDL-C and ApoB disagree, ApoB wins.
Why Cholesterol Numbers Tell Only Part of the Story
LDL and HDL cholesterol are among the most recognized health metrics in mainstream medicine. They appear on nearly every standard blood panel, they are the targets of some of the most widely prescribed medications ever developed, and they are referenced in nearly every cardiovascular risk discussion. They are also, in isolation, less informative than most people realize.
The fundamental limitation of LDL-C is that it measures the mass of cholesterol transported inside LDL particles, not the number of particles doing the transporting. This distinction matters because it is the LDL particle — not the cholesterol it carries — that penetrates arterial walls and initiates the plaque-forming process. Two people can have identical LDL-C values while having dramatically different numbers of LDL particles, and therefore dramatically different atherogenic risk.
This is not a fringe view — it is the scientific consensus among cardiovascular researchers and lipidologists. ApoB, which directly counts every atherogenic lipoprotein particle, is consistently superior to LDL-C as a cardiovascular risk predictor in head-to-head comparisons. Yet LDL-C remains the standard reported metric because it is cheap, widely available, and embedded in decades of clinical guidelines. Understanding both — what LDL-C shows and where it falls short — is essential for interpreting a lipid panel correctly.
LDL: Particle Size, Density, and Atherogenic Risk
Not all LDL particles are equally dangerous. LDL particles exist along a spectrum from large and buoyant (pattern A) to small and dense (pattern B), and the distribution of LDL particle size significantly affects cardiovascular risk beyond what LDL-C captures.
Small dense LDL particles are more atherogenic for several reasons. They penetrate arterial endothelium more readily due to their smaller diameter. They have reduced affinity for the LDL receptor, meaning they circulate longer before clearance. They are more susceptible to oxidative modification, and oxidized LDL is the primary trigger for macrophage foam cell formation and plaque development. Small dense LDL is also more prone to glycation in the context of insulin resistance, further increasing its atherogenicity.
LDL particle size cannot be determined from standard LDL-C alone — it requires either NMR spectroscopy (for direct particle sizing) or is approximated by the triglyceride-to-HDL ratio. The triglyceride:HDL ratio is a reliable indirect marker of LDL particle size: a ratio above 3.5 (mg/dL units) predicts predominantly small dense LDL (Pattern B), while a ratio below 2.0 predicts predominantly large buoyant LDL (Pattern A). This is one reason the triglyceride:HDL ratio is often more informative than LDL-C alone when assessing cardiovascular risk.
| LDL-C (mg/dL) | Standard Classification | Longevity Assessment |
|---|---|---|
| < 70 | Optimal | Longevity-optimal — target for aggressive cardiovascular prevention |
| 70–99 | Near optimal | Good — acceptable with favorable ApoB and particle profile |
| 100–129 | Borderline | Monitor — assess ApoB and particle characteristics |
| 130–159 | Borderline high | Elevated — warrants lifestyle optimization and ApoB assessment |
| ≥ 160 | High | High — intervention indicated; clinical evaluation if lifestyle-resistant |
Already have your lab results? See how your LDL, HDL and other markers score on a longevity scale — in under 60 seconds.
Analyze My Biomarkers →HDL: The Nuanced Story of 'Good' Cholesterol
HDL cholesterol is reliably described as the "good" cholesterol, and within a broad middle range this characterization is accurate. HDL particles perform reverse cholesterol transport — collecting cholesterol from peripheral tissues and arterial walls and returning it to the liver for processing and excretion. People with low HDL-C (below 40 mg/dL in men, below 50 mg/dL in women) have consistently higher rates of cardiovascular disease.
The relationship becomes more complex at higher HDL levels. Multiple large prospective studies have found a J-shaped or U-shaped relationship between HDL-C and cardiovascular outcomes — with the lowest risk in the 50–80 mg/dL range and paradoxically elevated risk above 90–100 mg/dL. The CANHEART study of over 600,000 participants found that men with HDL-C above 90 mg/dL had higher all-cause mortality than those with HDL-C of 60–90 mg/dL. 1
The probable explanation is that very high HDL-C often reflects dysfunctional HDL particles that have lost their capacity for effective reverse cholesterol transport. This can occur through several mechanisms: chronic alcohol consumption (which raises HDL-C substantially but produces dysfunctional particles), genetic variants that slow HDL clearance while impairing function, and inflammatory states that modify HDL protein composition. Critically, every major pharmaceutical attempt to raise HDL-C — niacin, CETP inhibitors — has failed to reduce cardiovascular events, strongly suggesting that HDL-C is a marker rather than a mediator of cardiovascular protection above a certain threshold.
| HDL-C (mg/dL) | Standard Classification | Longevity Assessment |
|---|---|---|
| < 40 (men) / < 50 (women) | Low — increased risk | Low — meaningful cardiovascular and metabolic risk signal |
| 40–59 | Acceptable | Acceptable — room for improvement |
| 60–80 | High — protective | Optimal — target range with consistent protective benefit |
| > 90–100 | Very high | Investigate — may reflect HDL dysfunction; paradoxically elevated risk in some studies |
The Ratios That Matter More Than Single Values
Because LDL-C and HDL-C are each incomplete on their own, their relationship to each other and to other markers provides more insight than any single value.
Total cholesterol-to-HDL ratio: Total cholesterol ÷ HDL-C. Values below 3.5 are associated with low cardiovascular risk; above 5.0 is elevated. This ratio has been used in Framingham risk scoring and captures both the LDL burden and the HDL protective context.
LDL-C-to-HDL-C ratio: LDL-C ÷ HDL-C. Below 2.5 is excellent; above 4.0 warrants attention. This ratio captures the balance between atherogenic and reverse transport particle activity.
Triglyceride-to-HDL ratio: As detailed in the triglycerides page, this ratio is one of the most powerful cardiovascular risk surrogates available from a standard lipid panel. It predicts LDL particle size and insulin resistance with high reliability. Below 1.5 is excellent; above 3.5 signals metabolic dysfunction and predominantly small dense LDL.
None of these ratios replace ApoB — which remains the gold standard for counting atherogenic particles. But they add interpretive depth to a standard lipid panel that reports only LDL-C and HDL-C in isolation.
How to Test and What to Order
LDL-C and HDL-C are included in every standard lipid panel and require a fasting blood draw (9–12 hours without food). Always order them alongside triglycerides, which are essential for context and for calculating the TG:HDL ratio.
For a complete cardiovascular risk assessment, add ApoB — the direct measure of atherogenic particle count. Many labs offer ApoB as an add-on to a standard lipid panel for $15–40. Also consider Lipoprotein(a) at least once — a genetically determined cardiovascular risk factor that requires no ongoing monitoring but is critical to know.
Annual testing as part of a comprehensive metabolic panel is appropriate for most adults. If LDL-C is elevated and you are implementing dietary changes or medications, retest at 3 months to assess response.
Sources
- Madsen CM, et al. "Extreme High High-Density Lipoprotein Cholesterol Is Paradoxically Associated with High Mortality in Men and Women." European Heart Journal, 2017. PubMed →
- Sniderman AD, et al. "A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non–High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk." Circulation: Cardiovascular Quality and Outcomes, 2011. PubMed →
| Range Type | Value (mg/dL) | Notes |
|---|---|---|
| Standard Clinical Range | LDL-C: < 100 mg/dL (optimal) · HDL-C: > 40 mg/dL (men), > 50 mg/dL (women) | Designed to identify disease risk — not longevity optimisation. |
| Longevity-Optimal Target | LDL-C: < 70 mg/dL · HDL-C: 50–80 mg/dL |
Associated with reduced all-cause mortality and extended healthspan.
The longevity-optimal LDL-C target reflects the level seen in populations with near-zero atherosclerotic disease and is the target used in aggressive cardiovascular prevention. For HDL-C, the protective benefit plateaus around 60–80 mg/dL — levels above this may reflect a dysfunctional HDL particle and are associated with paradoxically increased cardiovascular risk in some studies.
|
Already have your results? See what your LDL & HDL Cholesterol and other markers reveal about your longevity in 60 seconds.
Analyze My Labs →Affiliate disclosure: we may earn a commission if you purchase through these links at no extra cost to you.
Why is LDL-C an imperfect cardiovascular risk marker?
LDL-C measures the total mass of cholesterol carried inside LDL particles, but it is the number and size of LDL particles — not their cholesterol cargo — that determines how many opportunities there are for arterial wall penetration and plaque formation. A person with large, buoyant LDL particles and an LDL-C of 130 mg/dL may have fewer atherogenic particles than someone with small, dense LDL and an LDL-C of 100 mg/dL. The same cholesterol mass packed into more, smaller particles means more particles available to penetrate arterial walls. ApoB directly counts the particles (one ApoB per atherogenic particle) and is therefore a more accurate predictor of cardiovascular risk than LDL-C in most population studies.
Is higher HDL always better?
Not necessarily. HDL-C in the range of 50–80 mg/dL is consistently associated with cardiovascular protection. Above this range, the evidence is more complex. Several large cohort studies have found a U-shaped relationship between HDL-C and cardiovascular risk, with very high HDL-C (above 90–100 mg/dL in men, above 100–120 mg/dL in women) associated with paradoxically increased cardiovascular and all-cause mortality. The likely explanation is that very high HDL-C often reflects dysfunctional HDL particles — unable to perform reverse cholesterol transport effectively — rather than supranormal protective HDL. Genetic studies artificially raising HDL-C have consistently failed to reduce cardiovascular events, further suggesting that HDL-C is a marker rather than a mediator of cardiovascular protection in the upper range.
What is the difference between LDL-C and LDL-P (particle number)?
LDL-C is the cholesterol concentration within LDL particles, measured in mg/dL. LDL-P (LDL particle number) counts the actual number of LDL particles per unit volume, measured by NMR spectroscopy in nmol/L. These values often agree, but diverge when LDL particles are unusually small (high particle number with lower cholesterol content per particle) or unusually large (lower particle number with higher cholesterol content). When LDL-C and LDL-P diverge, LDL-P is the better predictor of cardiovascular risk. ApoB serves as a reliable surrogate for LDL-P on a standard blood draw without requiring specialized NMR testing — since each LDL particle carries exactly one ApoB molecule, ApoB directly reflects particle number.
How do diet and exercise affect LDL and HDL?
Saturated fat intake raises LDL-C, while replacing saturated fat with unsaturated fat lowers it. Statins and other cholesterol-lowering medications primarily reduce LDL-C through hepatic LDL receptor upregulation. For HDL-C, aerobic exercise is the most reliable lifestyle intervention — consistent endurance exercise raises HDL-C by 3–9 mg/dL in most studies. Losing excess weight, quitting smoking, and reducing refined carbohydrates (which raise triglycerides and lower HDL) also improve HDL-C. Alcohol in moderate amounts raises HDL-C, but the net health tradeoff of alcohol makes it an inappropriate intervention. No current medication reliably raises HDL-C in a way that translates to reduced cardiovascular events.
Should I be concerned if my LDL goes up on a low-carb or ketogenic diet?
Some people experience significant LDL-C elevation on very low-carbohydrate or ketogenic diets — often accompanied by large, buoyant LDL particles that may be less atherogenic than the elevated absolute number suggests. However, ApoB typically tracks the atherogenic risk more accurately than LDL-C in this context. If LDL-C rises on a low-carb diet, the most important question is whether ApoB is rising proportionally. If LDL-C rises substantially but ApoB is stable or mildly elevated with improved triglycerides and HDL, the risk picture may be less concerning than the LDL number alone implies. If ApoB is rising significantly, the diet change warrants reconsideration or medical evaluation regardless of the LDL particle size narrative.